Islet cell transplantation

Postgraduate Medical Journal

Volumn 83, Issue 978, 2007, Pages 224-229

  Srinivasan, P ^a   Huang, G C ^a   Amiel, S A ^a   Heaton, N D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BELATACEPT; C PEPTIDE; CARBAMAZEPINE; DACLIZUMAB; ESTRADIOL; GABAPENTIN; INSULIN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; GLYCEMIC CONTROL; GRAFT REJECTION; HISTORY OF MEDICINE; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL NEUROPATHY; PROTEIN SECRETION; REVIEW;

DIABETES MELLITUS, TYPE 1; FORECASTING; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSION; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; PATIENT SELECTION; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 34247474712     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.053447     Document Type: Review

References (51)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-86.
2. American Diabetes Association. Pancreas transplantation for patients with type 1 diabetes: American Diabetes Association. Diabetes Care 2000;23:117.
3. American Diabetes Association. Pancreas transplantation for patients with type 1 diabetes: American Diabetes Association. Diabetes Care 2003;26:120.
4. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in 7 patients with type1 diabetes mellitus using a glucocorticoid-free immunosuppression regimen. N Engl J Med 2000;343:230-8.
5. Ault A. Edmonton's islet success tough to duplicate elsewhere. Lancet 2003;361:2054.
6. Shapiro AM, Ricordi C, Hering B. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003;9391:1242.
7. Ballinger WF, Lacey PE. Transplantation of intact pancreatic islets in rats. Surgery 1972;72:175-86.
8. Najarian JS, Sutherland DE, Baumgartner D, et al. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg 1980;192:526-42.
9. Pyzdrowski KL, Kendall DM, Halter JB, et al. Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl J Med 1992;327:220-6.
10. Largiader F, Kolb E, Binswanger U. A long-term functioning human pancreatic islet allotransplant. Transplantation 1980;29:76-7.
11. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53:955-62.
12. Rodrigues IAS, Reid HA, Ismail K, et al. Indications and efficacy of continuous subcutaneous insulin infusion (CS11) therapy in type 1 diabetes mellitus: a clinical audit in a specialist service. Diabetic Medicine 2005;22:842-9.
13. Shapiro J, Ryan E, Warnock GL, et al. Could fewer islet cells be transplanted in type 1 diabetes? Insulin independence should be dominant force in islet transplantation. BMJ 2001;322:861.
14. Ryan EA, Lakey JRT, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 2001;50:710-19.
15. Ryan EA, Lakey JRT, Paty BW, et al. Continued insulin reserve provides long-term glycemic control. Diabetes 2002;51:2148-58.
16. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9.
17. Clarke WL, Gonder- Fredrick LA, Richards FE, et al. Multifactorial origin of hypoglycemic symptom unawareness in IDDM. Association with defective glucose counterregulation and better glycemic control. Diabetes 1991;40:680-5.
18. O'Gorman D, Kin T, Murdoch T, et al. The standardization of pancreatic donors for islet isolations. Transplantation 2005;80:801-6.
19. Brandhorst H, Brandhorst D, Hering BJ, et al. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes 1995;103(Suppl 2):23.
20. Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 1996;61:1047.
21. Powner DJ. Donor care before pancreatic tissue transplantation. Prod Trans 2005;15:129-36.
22. Lee TC, Barshes NR, Brunicardi FC, et al. Procurement of the human pancreas for pancreatic islet transplantation. Transplantation 2004;15:81-3.
23. Evans M, Amiel SA. Hypoglycemia. In: Wass JA, Shallet S, Gale EAM, Amiel SA, eds. Textbook of endocrinology. Oxford: OUP, 1717-26).
24. Smith D, Pernet A, Rosenthal JM, et al. The effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia. Diabetologia 2004;47:1704-11.
25. Matsumoto S, Tanaka K. Pancreatic islet cell transplantation using non-heart-beating donors (NHBDs). J Hepatobiliary Pancreat Surg 2005;12:227-30.
26. Matsumoto S, Tanaka K, Strong DM, et al. Efficacy of human islet isolation from the tail section of the pancreas for the possibility of living donor islet transplantation. Transplantation, 2004 27, 78:39-43.
27. Matsumoto S, Okitsu T, Iwanaga Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005;365:1642-4.
28. Amiel SA, Rela M. Live organ-donation for islet transplantation. Lancet 2005;365:1603-4.
29. Tsujimura T, Kuroda Y, Avila JG, et al. Influence of pancreas preservation on human islet isolation outcomes: impact of the two-layer method. Transplantation 2004;78:96-100.
30. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005;5:2037- 46.
31. Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000;105:125-33.
32. Hafiz MM, Faradji RN, Froud T, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005;80:1718-28.
33. Brennan DC, Shannon MB, Koch MJ, et al. Portal vein thrombosis complicating islet transplantation in a recipient with the factor V Leiden mutation. Transplantation 2004;78:172-3.
34. Hopkins Tanne J. New technique improves safety of islet cell transplantation. BMJ 2005;331:1290.
35. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-9.
36. Gerber PA, Pavlicek V, Zuellig R, et al. Which to prefer: simultaneous islet-kidney or pancreas-kidney transplantation in typel diabetes mellitus: a six year single center follow-up. Diabetologia. 2006;49: OP 42, (Suppl 1).
37. Frank A, Deng S, Huang X, et al. Transplantation for type i diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. 240:631-43.
38. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:30-5.
39. Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 2004;114:877-83.
40. Couzin J. Diabetes. Islet transplants face test of time. Science 2004;306:34-7.
41. Shapiro AMJ, Geng Hao E, Lakey JRT, et al. Novel approaches toward early diagnosis of islet allograft rejection. Transplantation 2001;71:1709-18.
42. Ryan EA, Paty BW, Senior PA, et al. Beta-score: An assessment of beta-cell function after islet transplantation. Diabetes Care 2005;28:343-8.
43. Shapiro AM, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation 2005;79:1304-7.
44. Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant 2003;3:794- 803.
45. Dufour JM, Rajotte RV, Zimmerman M, et al. Development of an ectopic site for islet transplantation, using biodegradable scaffolds. Tissue Eng 2005;11:1323-31.
46. Yin D, Ding JW, Shen J, et al. Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant 2006;6:60-8.
47. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006;19:705-14.
48. Ridgway DM, White SA, Kimber RM, et al. Current practices of donor pancreas allocation in the UK: future implications for pancreas and islet transplantation. Transpl Int 2005;18:828-34.
49. Sudo T, Hiyama E, Murakami Y, et al. Hepatic regeneration promotes engraftment of intraportally transplanted islet cells. Surgery 2005;137:612-9.
50. Street CN, Lakey JR, Shapiro AM, et al. Islet graft assessment in the Edmonton protocol: implications for predicting long-term clinical outcome. Diabetes 2004;53:3107-14.
51. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with typel diabetes. JAMA 2005;293:830-5.